[
  {
    "ts": null,
    "headline": "How Recent Developments Are Rewriting the Story for Biogen",
    "summary": "Biogen’s fair value estimate has seen a modest uptick, now set at $178.07 compared to the previous $176.72. This change reflects slightly improved analyst confidence, supported by optimism around policy headwinds and progress in the company’s drug pipeline. Stay tuned to discover how investors can monitor these evolving narratives as market sentiment shifts. Analyst Price Targets don't always capture the full story. Head over to our Company Report to find new ways to value Biogen. What Wall...",
    "url": "https://finnhub.io/api/news?id=cded2af6c5c16164b0b0d5eacebc2b05b6daf1d756203c0b299b8aa46a521b3e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764227429,
      "headline": "How Recent Developments Are Rewriting the Story for Biogen",
      "id": 137619332,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Biogen’s fair value estimate has seen a modest uptick, now set at $178.07 compared to the previous $176.72. This change reflects slightly improved analyst confidence, supported by optimism around policy headwinds and progress in the company’s drug pipeline. Stay tuned to discover how investors can monitor these evolving narratives as market sentiment shifts. Analyst Price Targets don't always capture the full story. Head over to our Company Report to find new ways to value Biogen. What Wall...",
      "url": "https://finnhub.io/api/news?id=cded2af6c5c16164b0b0d5eacebc2b05b6daf1d756203c0b299b8aa46a521b3e"
    }
  }
]